Claims
- 1. (canceled)
- 2. (currently amended) the composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by formula (I):
- 3. The composition according to claim 2, wherein the sterol or 5α-stanol absorption inhibitor is represented by Formula (III) below:
- 4. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (III):
- 5. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (IV):
- 6. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (V):
- 7. The composition according to claim 11, where the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (VI):
- 8. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (VIIA) or (VIIB):
- 9. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (VIII):
- 10. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (IX):
- 11. A composition comprising:
(a) at least one antidiabetic medication selected from the group consisting of sulfonylurea, meglitinide, biguanide, thiazolidinedione, alpha-glucosidase inhibitor; peptide for increasing insulin production, and combinations thereof for reducing blood glucose levels in a subject; and (b) at least one sterol absorption inhibitor or at least one 5α-stanol absorption inhibitor, or a pharmaceutically acceptable salt or solvate thereof.
- 12. The composition according to claim 11, wherein the sulfonylurea is selected from the group consisting of acetohexamide, chlorpropamide, gliamilide, gliclazide, glimepiride, glipizide, glyburide, glibenclamide, tolazamide, tolbutamide, and combinations thereof.
- 13. The composition according to claim 11, wherein the meglitinide is selected from the group consisting of repaglinide, nateglinide and combinations thereof.
- 14. The composition according to claim 11, wherein the biguanide is selected from the group consisting of metformin, buformin, and combinations thereof.
- 15. The composition according to claim 11, wherein the alpha-glucosidase inhibitor is selected from the group consisting of acarbose, miglitol, camiglibose, voglibose, and combinations thereof.
- 16. The composition according to claim 11, wherein the peptide is selected from the group consisting of amlintide, pramlintide, exendin, GLP-1 agonistic peptides, and combinations thereof.
- 17. The composition according to claim 11, wherein the at least one antidiabetic medication is administered to a subject in an amount ranging from about 0.1 to about 1000 milligrams of antidiabetic medication per day.
- 18. The composition according to claim 11, wherein the at least one sterol or 5α-stanol absorption inhibitor is administered to a subject in an amount ranging from about 0.1 to about 1000 milligrams of sterol or 5α-stanol absorption inhibitor per day.
- 19. The composition according to claim 11, wherein the at least one antidiabetic medication is orally administrable insulin or insulin composition for intestinal delivery thereof in a therapeutically effective amount.
- 20. A pharmaceutical composition for the treatment or prevention of diabetes and lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising a therapeutically effective amount of the composition of claim 11 and a pharmaceutically acceptable carrier.
- 21. A pharmaceutical composition for the treatment or prevention of type 1 or type 2 diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising a therapeutically effective amount of the composition of claim 20 and a pharmaceutically acceptable carrier.
- 22. A method of treating or preventing diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising the step of administering to a subject in need of such treatment an effective amount of the composition of claim 1.
- 23. A method of treating or preventing type 1 or type 2 diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising the step of administering to a subject in need of such treatment an effective amount of the composition of claim 19.
- 24. A therapeutic combination comprising:
(a) a first amount of at least one antidiabetic medication selected from the group consisting of sulfonylurea, meglitinide, biguanide, thiazolidinedione, alpha-glucosidase inhibitor; peptide for increasing insulin production, and combinations thereof for reducing blood glucose levels in a subject; and (b) a second amount of at least one sterol or 5α-stanol absorption inhibitor; wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject.
- 25. The therapeutic composition according to claim 24, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (I):
- 26. The therapeutic composition according to claim 24, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (II):
- 27. A therapeutic combination according to claim 24, wherein the at least one antidiabetic medication is administered concomitantly with the at least one sterol or 5α-stanol absorption inhibitor.
- 28. A therapeutic combination according to claim 24, wherein the at least one antidiabetic medication and the at least one sterol or 5α-stanol absorption inhibitor are present in separate treatment compositions.
- 29. A method of treating or preventing diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising the step of administering to a subject in need of such treatment an effective amount of the therapeutic combination of claim 24.
- 30. A composition comprising: (a) at least one antidiabetic medication selected from the group consisting of sulfonylurea, meglitinide, biguanide, thiazolidinedione, alpha-glucosidase inhibitor; peptide for increasing insulin production, and combinations thereof; and (b) at least one substituted azetidinone compound or a pharmaceutically acceptable salt thereof or a solvate thereof.
- 31. A pharmaceutical composition for the treatment or prevention of diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising a therapeutically effective amount of the composition of claim 30 and a pharmaceutically acceptable carrier.
- 32. A method of treating or preventing diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject, comprising the step of administering to a subject in need of such treatment an effective amount of the composition of claim 30.
- 33. A therapeutic combination comprising:
(a) a first amount of at least one antidiabetic medication selected from the group consisting of sulfonylurea, meglitinide, biguanide, thiazolidinedione, alpha-glucosidase inhibitor; peptide for increasing insulin production, and combinations thereof for reducing blood glucose levels in a subject; and (b) a second amount of at least one substituted azetidinone compound or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of diabetes or lowering a concentration of a sterol or 5α-stanol in plasma of a subject.
- 34. A method of treating or preventing diabetes in a subject, comprising the step of administering to a subject in need of such treatment an effective amount of a composition comprising at least one sterol or 5α-stanol absorption-inhibitor.
- 35. A method of treating or preventing diabetes in a subject, comprising the step of administering to a subject in need of such treatment an effective amount of a composition comprising at least one sterol or 5α-stanol absorption inhibitor represented by Formula (II) below:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority from U.S. Provisional Patent Application Ser. No. 60/323,841 filed Sep. 21, 2001, and is a continuation-in-part of U.S. patent application Ser. No. 10/166,942 filed Jun. 11, 2002 and is a continuation-in-part of U.S. patent application Ser. No. 10/057,323 filed Jan. 25, 2002, which claims the benefit of priority from U.S. Provisional Patent Application Ser. No. 60/264,396, filed Jan. 26, 2001 and U.S. Provisional Patent Application Ser. No. 60/323,839, filed Sep. 21, 2001, each incorporated herein by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60323841 |
Sep 2001 |
US |
|
60264396 |
Jan 2001 |
US |
|
60323839 |
Sep 2001 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10166942 |
Jun 2002 |
US |
Child |
10247099 |
Sep 2002 |
US |
Parent |
10057323 |
Jan 2002 |
US |
Child |
10247099 |
Sep 2002 |
US |